143 related articles for article (PubMed ID: 36709169)
1. [In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
Wang J; Zhao AL; Li H; Yang LY; Chen LJ; Niu T
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):753-759. PubMed ID: 36709169
[No Abstract] [Full Text] [Related]
2. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
3. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of
Yang L; Qiu Q; Tang M; Wang F; Yi Y; Yi D; Yang Z; Zhu Z; Zheng S; Yang J; Pei H; Zheng L; Chen Y; Gou L; Luo L; Deng X; Ye H; Hu Y; Niu T; Chen L
Clin Cancer Res; 2019 Dec; 25(24):7527-7539. PubMed ID: 31439580
[TBL] [Abstract][Full Text] [Related]
4. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Kim SJ; Kim UJ; Yoo HY; Choi YJ; Kang KW
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575557
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
6. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
Zhao X; Yang W; Shi C; Ma W; Liu J; Wang Y; Jiang G
Tumour Biol; 2011 Apr; 32(2):335-46. PubMed ID: 21113745
[TBL] [Abstract][Full Text] [Related]
7. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.
Mathew OP; Ranganna K; Yatsu FM
Biomed Pharmacother; 2010 Dec; 64(10):733-40. PubMed ID: 20970954
[TBL] [Abstract][Full Text] [Related]
8. [The effect of apoptosis induced by IL-21 in SUDHL-4 cell line and its mechanism].
Liang W; Zhang WJ; Gao QM; Qin W; Lu HN; Huang BB; Xiu B; Liang AB
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):402-5. PubMed ID: 22781801
[TBL] [Abstract][Full Text] [Related]
9. Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells.
Pal-Bhadra M; Ramaiah MJ; Reddy TL; Krishnan A; Pushpavalli SN; Babu KS; Tiwari AK; Rao JM; Yadav JS; Bhadra U
BMC Cancer; 2012 May; 12():180. PubMed ID: 22591439
[TBL] [Abstract][Full Text] [Related]
10. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
11. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines.
Ma J; Guo X; Zhang S; Liu H; Lu J; Dong Z; Liu K; Ming L
Mol Med Rep; 2015 Jun; 11(6):4525-31. PubMed ID: 25634603
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
15. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F
Oncotarget; 2015 Mar; 6(7):5059-71. PubMed ID: 25671298
[TBL] [Abstract][Full Text] [Related]
16. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
17. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
18. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition.
Findeisen HM; Gizard F; Zhao Y; Qing H; Heywood EB; Jones KL; Cohn D; Bruemmer D
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):851-60. PubMed ID: 21233448
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and evaluation of Cd[L-proline]
Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
